Quick Answer
Rein Therapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
Rein Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $0.00 | — |
| 2024 | $0.00 | — |
| 2023 | $0.00 | — |
| 2022 | $0.00 | — |
| 2021 | $0.00 | — |
| 2020 | $0.00 | — |
| 2019 | $0.00 | — |
| 2018 | $0.00 | — |
| 2017 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | — | — |
| June 30, 2025 | $0.00 | — | — |
| March 31, 2025 | $0.00 | — | — |
| September 30, 2024 | $0.00 | — | — |
| June 30, 2024 | $0.00 | — | — |
| March 31, 2024 | $0.00 | — | — |
| September 30, 2023 | $0.00 | — | — |
| June 30, 2023 | $0.00 | — | — |
- The most recent figure is from Rein Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: